Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trialIsabelle Andrieux‐Meyer, Shahnaz Murad, Caroline Menétrey et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 42
Efficacy and Safety of Ravidasvir Plus Sofosbuvir in Chronic Hepatitis C Infected Subjects Without Cirrhosis or with Compensated Cirrhosis: Interim Analysis Results of a Two-Stage, Open-Label, Multicentre, Phase 2/3 TrialIsabelle Andrieux‐Meyer, Shahnaz Murad, Soek-Siam Tan et al.|SSRN Electronic Journal|2020Cited by 0